Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 21 -26 of 26 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/22/2008 First Published: 5/23/2005


21.		Phase II Study of FR901228 (Depsipeptide) in Patients With Metastatic or Unresectable Soft Tissue Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CCCWFU-71103 6319, NCT00112463, CCCWFU 71103

Last Modified: 11/1/1999


22.		Phase I Study of Intravenous Depsipeptide for Refractory Advanced Adult Malignancies (Summary Last Modified 11/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				GUMC-95066 GUMC-T95-0022, NCI-T95-0022D, T95-0022

Last Modified: 10/1/2001


23.		Phase I Study of Depsipeptide in Patients With Incurable Solid Tumors (Specifically Cutaneous T-Cell Lymphoma) (Summary Last Modified 10/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NCI-97-C-0135G NCI-T95-0077, NCT00019318, T95-0077

Last Modified: 6/28/2006 First Published: 9/1/2001


24.		Phase I Study of FR901228 (Depsipeptide) in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				OSU-00H0350 NCI-27, NCT00024180, 27

Last Modified: 12/13/2007 First Published: 1/26/2003


25.		Phase I Study of FR901228 (Depsipeptide) in Pediatric Patients With Refractory or Recurrent Solid Tumors or Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				Under 22				NCI				COG-ADVL0212 NCI-03-C-0307, NCT00053963, ADVL0212

Last Modified: 10/31/2006 First Published: 6/8/2005


26.		Phase I Study of Decitabine and FR901228 (Depsipeptide) in Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				Over 18				NCI				MDA-2004-0674 5563, NCI-5563, NCT00114257

Select All on One Page


					< Previous 1 2 3